Hussein Sweiti - 30 Sep 2025 Form 4 Insider Report for enGene Holdings Inc. (ENGN)

Role: Chief Medical Officer
Signature: /s/ Lee Giguere, as attorney-in-fact for the Reporting Person
Issuer symbol: ENGN
Transactions as of: 30 Sep 2025
Net transactions value: $0
Form type: 4
Filing time: 01 Oct 2025, 16:54:55 UTC
Previous filing: 01 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Sweiti Hussein	Chief Medical Officer	C/O 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, QUEBEC, CANADA	/s/ Lee Giguere, as attorney-in-fact for the Reporting Person	01 Oct 2025	0002088436

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENGN	Stock Option (Right to Buy)	Award	$0	+600,000		$0.000000	600,000	30 Sep 2025	Common Shares	600,000	$6.83	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Non-qualified stock option grant awarded as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on September 29, 2026, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to the reporting person's continued service.

Content

Non-qualified stock option grant awarded as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on September 29, 2026, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to the reporting person's continued service.